• COVID-19: Who is at risk of secondary pulmonary fibrosis?

    Pulmonary fibrosis can occur secondarily after infection, especially in patients who suffered from severely impaired diffusion capacity during the acute infection.

  • COPD: Singing training as effective as physical rehabilitation

    Singing is as effective as classical pulmonary rehabilitation in COPD patients as a means of improving physical performance.

  • Sleep apnea: Improved AHI through physical activity

    Physical activity should play a key role in multi-component interventions of sleep apnea patients as it has a positive influence on the Apnea-Hypopnea Index and risk factors for diseases such as diabetes.

  • A danger underestimated: Nicotine products consumption and the lungs

    An increasing variety of nicotine-containing products is available. The consumption of e-cigarettes, traditional cigarettes, and also cannabis, could be more harmful than smoking alone.

  • Low intensity smoking: An underestimated risk?

    Results from a large pooled cohort study show that even less than 10 cigarettes a day significantly increases the risk of lung cancer or respiratory disease death.

  • New treatment option for chronic hypercapnic COPD

    Nasal high-flow therapy and non-invasive ventilation performed equally well in people with cCOPD with hypercapnia. NHF could therefore be a valuable addition to existing oxygen delivery devices.

  • COVID-19: Detecting persistent lung damage through structured aftercare

    People infected with COVID-19 often suffer long-term lung function impairment, but preliminary CovILD study results found improvement over time for many patients.

  • App for measuring nocturnal cough detects worsening of asthma

    Objective markers for asthma-like coughs can be measured via a smartphone. This technology could solve the current problems in monitoring respiratory diseases.

  • Cognitive decline due to a reduced lung function?

    An analysis of longitudinal data found an association between lung function and cognitive impairment in older people over an average 12-years follow-up period.